Literature DB >> 23526366

Secreted recombinant P53 protein from Pichia pastoris is a useful antigen for detection of serum p53: autoantibody in patients with advanced colorectal adenocarcinoma.

Salma Abdelmoula-Souissi1, Nourane Zouari, Imen Miladi-Abdenadher, Ouhoud Yaich-Kolsi, Ines Ayadi-Masmoudi, Abdelmajid Khabir, Hatem Masmoudi, Mounir Frikha, Raja Mokdad-Gargouri.   

Abstract

The detection of P53 alteration by serological method is easier to perform, does not require tumor tissues and is of interest for patients monitoring. In this study, we described the development of a home made ELISA test based on recombinant human P53 protein produced in Pichia pastoris and used as antigen for the detection of serum p53-Abs in colorectal carcinoma patients. The human P53 was secreted as a His-tagged protein by recombinant KM71 strain (Kα21) via the peptide signal α of the Saccharomyces cerevisiae mating type gene. The recombinant P53-His was able to detect p53-Abs in 23.4% of patients. Serum p53-Abs correlated significantly with surgical treatment (P = 0.007), relapse during follow-up (P = 0.036), depth of invasion (P = 0.036) and the level of CA19-9 (P = 0.034). Survival analysis showed that patients negative for serum p53-Abs exhibited a prolonged disease free survival period (P log rank = 0.012). In conclusion, the secreted recombinant human P53-His produced in P. pastoris seems to be a useful antigen for detection of serum p53 Abs in patients with colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23526366     DOI: 10.1007/s11033-012-2467-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  38 in total

1.  Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.

Authors:  P Hammel; B Boissier; M T Chaumette; P Piedbois; N Rotman; J C Kouyoumdjian; R Lubin; J C Delchier; T Soussi
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients.

Authors:  R Tang; M C Ko; J Y Wang; C R Changchien; H H Chen; J S Chen; K C Hsu; J M Chiang; L L Hsieh
Journal:  Int J Cancer       Date:  2001-12-15       Impact factor: 7.396

Review 3.  Heterologous protein production using the Pichia pastoris expression system.

Authors:  Sue Macauley-Patrick; Mariana L Fazenda; Brian McNeil; Linda M Harvey
Journal:  Yeast       Date:  2005-03       Impact factor: 3.239

4.  Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors.

Authors:  Y Shibata; H Kotanagi; H Andoh; K Koyama; H Itoh; S Kudo
Journal:  Dis Colon Rectum       Date:  1996-11       Impact factor: 4.585

5.  High-level expression of human tumour suppressor P53 in the methylotrophic yeast: Pichia pastoris.

Authors:  Salma Abdelmoula-Souissi; Leila Rekik; Ali Gargouri; Raja Mokdad-Gargouri
Journal:  Protein Expr Purif       Date:  2007-03-28       Impact factor: 1.650

Review 6.  TP53 tumor suppressor gene: a model for investigating human mutagenesis.

Authors:  C Caron de Fromentel; T Soussi
Journal:  Genes Chromosomes Cancer       Date:  1992-01       Impact factor: 5.006

7.  Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up.

Authors:  A Suppiah; A Alabi; L Madden; J E Hartley; J R T Monson; J Greenman
Journal:  Int J Colorectal Dis       Date:  2008-03-11       Impact factor: 2.571

8.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

Authors:  A D Thor; I I Moore DH; S M Edgerton; E S Kawasaki; E Reihsaus; H T Lynch; J N Marcus; L Schwartz; L C Chen; B H Mayall
Journal:  J Natl Cancer Inst       Date:  1992-06-03       Impact factor: 13.506

Review 9.  Surf the post-translational modification network of p53 regulation.

Authors:  Bo Gu; Wei-Guo Zhu
Journal:  Int J Biol Sci       Date:  2012-05-10       Impact factor: 6.580

10.  Increased p53 protein content of colorectal tumours correlates with poor survival.

Authors:  Y Remvikos; O Tominaga; P Hammel; P Laurent-Puig; R J Salmon; B Dutrillaux; G Thomas
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.